Kate FynesInvestigator, Cell & Gene Therapy Product Development at GlaxoSmithKline
Kate graduated from the Biochemical Engineering department of University College London with a PhD in Stem Cell Bioprocessing, before undertaking a Postdoctoral position at the Institute of Ophthalmology. Here, as part of The London Project, she helped deliver an embryonic-stem cell derived-ATMP to treat age-related Macular Degeneration from the bench to the clinic as part of a Phase I/II clinical trial.
She joined GSK’s Cell & Gene Therapy - Product Development team in 2017, where she works to deliver the CMC aspects of various projects from early phase to launch. Kate specializes in Cell Process Development, seeking to optimize the manufacture of cell and gene therapy-based treatments, using increased automation and leading-edge processing technology.